Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02532231
Title Nivolumab in AML in Remission at High Risk for Relapse
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST